Cleaning validation. Presented by Marc Fini 21 May, 2013

Similar documents
US FDA Process Validation Guidance. Presented by Marc Fini 21 May, 2013

New Annex 15 Updated Requirements & Approach to Validation. Presented by Ashley Isbel 10 th August 2015

Technical Monograph n 17, 2nd Edition. Guidelines for Specifying the Shelf Life of Plant Protection Products

Excipient Risk Assessment

PMTC Knowledge Day 2017 August 31 st Cleaning validation hot topics. THOMAS ALTMANN. Global Technical Manager ECOLAB LIFE SCIENCES RD&E.

Deviations Inspection Observations & Issues to Consider for Achieving Compliance

Defining, achieving, and demonstrating effective performance of containment systems. Gordon Farquharson, July 2017

Allergen Cleaning, Verification & Validation

Analytical method validation. Presented by Debbie Parker 4 July, 2016

Cross Contamination & the EU GMP Guide. Bryan J Wright July 2017

Product Information Dairy

General concepts in the Ph. Eur.: theory and rationale

EU Regulatory Update & GMP Deficiencies. Bryan J Wright July 2017

Achieving Effective and Reliable NDT in the Context of RBI

M6-C Artificial Cervical Disc Surgical Instruments

Healthcare Sterilisation: Challenging Practices Volume 2

C.17. HONEYBEES - AC UTE CONTACT TOXICITY TEST. This acute toxicity test method is a replicate of the OECD TG 214 (1998).

IPEC Europe Suggested Alternative (if none then original text is clear and needs no alteration) Purpose and Scope

1. Module Details PENETRANT TESTING. 2. Module Purpose To enable students to develop a detailed understanding of the

Cleaning and Allergens

ProUltra ULTRASONIC SURGICAL TIPS

Allergen Control in the Food Plant

Savesta Herbals is engaged in manufacturing

UNICLIP DIRECTIONS FOR USE REF C226U - 0,8 MM / 1 MM FOR DENTAL USE ONLY. FISDR / F EN / 11 / updated 06/2016 1/7

Uni-directional Airflow Systems Working Height Velocity (WHV) Gordon Farquharson July 2017

ASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC

PDA Points to Consider relating to EU GMP Annex 1 changes. Presented by Ashley Isbel 30 November, 2016

Setting up deviation, incident, nonconformance. Presented by Debbie Parker 4 July, 2016

General Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

Decentralised Procedure. Public Assessment Report

Reprocessing Guide. Autoclavable Arthroscope and Hardware Sterilization Tray

Dose Audits 101 February 4, 2016

SCIENTIFIC DISCUSSION. AkuriT-3 Tablets*

Final Report. Acute dermal toxicity study in Wistar rats. Mr. M. Vasanthan, M Tech (Biotech)

Sterility Assurance and Risk Management: A CDER Microbiologist s Perspective

Partner with the Global Leader in Drug Delivery Systems

Scope This policy applies to all personnel and departments that clean, prepare and/or sterilize items intended for patient care use.

PinPrick Stimulator Set

The AAMI Impact: What Dentistry Can Learn from AAMI ST79. Best Practices for device and instrument reprocessing

Velocity Orthopedics Instrument Cleaning and Sterilization

Single market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations

SCIENTIFIC DISCUSSION

ProUltra Ultrasonic Non Surgical Endo Tips

Mylan Laboratories Limited F-4 & F-12, Malegaon MIDC, Sinnar Nashik Maharashtra State, India

SURFACE VEHICLE INFORMATION REPORT

C.16. HONEYBEES - AC UTE ORAL TOXICITY TEST. This acute toxicity test method is a replicate of the OECD TG 213 (1998).

Liquid Penetrant Test [7] Introduction to Nondestructive Testing (NDT)

Power-Pak 445 Adjustable Dumbbell System

Environmental Monitoring How to Satisfy the Regulator. Presented by Tanja Varglien, July 2017

For use by an Accredited Orthopaedic Surgeon only

LIQUID PREPARATIONS FOR ORAL USE. Final text for addition to The International Pharmacopoeia (November 2007)

1) INDICATIONS FOR USE These products have to be used only in hospital environments, clinics or dental offices by qualified dental personnel.

Decentralised Procedure. Public Assessment Report. Budesonid Sandoz 32 / 64 Mikrogramm/Sprühstoß Nasenspray, Suspension.

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

Manufacturer s information

CHAPTER 2 SIMULTANEOUS DETRMINATION OF ANASTROZOLE AND TEMOZOLOMIDE TEMOZOLOMIDE CAPSULES 20 MG AND ANASTROZOLE TABLETS 1 MG

Soluplus The Solid Solution Opening New Doors in Solubilization.

LPI Recertification Written Instruction Guidelines

SCIENTIFIC DISCUSSION. Lopinavir and Ritonavir 200 mg/50 mg Tablets * Name of the Finished Pharmaceutical Product:

Method References for WuXi AppTec s Microbiology, Chemistry and Package Testing

TECHNICAL CHARACTERISTICS CT 037

INSTRUCTIONS FOR CLEANING, DISINFECTION AND STERILIZATION OF DFS INSTRUMENTS

SAFETY DATA SHEET (91/155/EC) IDENTIFICATION OF THE SUBSTANCE /

BMA INFORMATION BULLETIN No. 23. International Safety Management (ISM) Code

: Corian Joint Adhesive Kit - Component A

247 CMR BOARD OF REGISTRATION IN PHARMACY

ADVANCED VAPOUR DEGREASING WITHOUT OZONE DEPLETING SOLVENTS

Public Assessment Report Scientific discussion

SOFT GELATIN CAPSULE. Dr. Nawal Ayash

No. GA Page 1 of 7 Effective Date: 03/04/ CFR (c), ANSI/ISEA Z TITLE: Chancellor Date: 03/04/16

FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS. ZINEB Zinc ethylenebisdithiocarbamate

Decentralised Procedure. Public Assessment Report. Zolmitriptan Renantos 2.5 mg Orodispersible film 5 mg Orodispersible film DE/H/2295/ /DC

MATERIAL SAFETY DATA SHEET (MSDS) Information about stainless steel for Surgical/Dental/Orthodontic Instruments.

SPECTINOMYCIN DIHYDRCHLORIDE PENTAHYDRATE

TECHNICAL NOTE SURFACE PREPARATION GUIDE

Overview Internal review

CORESTA RECOMMENDED METHOD N 8


Addendum to the 2016 FAO/WHO Manual on pesticide specifications: revised Tablet Specifications for DT, ST and WT

The Cannabis Workflow and the IMPORTANCE OF TEMPERATURE CONTROL

Public Assessment Report Scientific discussion

AGP: CP/89 FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS. PHENTHOATE S - a - ethoxycarbonylbenzyl 00-dimethyl phosphorodithioate

Global Standards Engineering Policy & Procedure

FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS. BROMOPHOS 4-bromo-2,5-dichloropheny1 dimethy1 phosphorothioate

SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Topics covered by the talk

July 11, Dear Mr. Derfler:

Stax Disposable Depth Filters

SCIENTIFIC DISCUSSION

SAFETY SHOWERS AND EYEWASHES 1.01 RELATED CORNELL DESIGN AND CONSTRUCTION STANDARDS

IAS Presentation at Kuwait Labs nd Kuwait Conference for Laboratory Quality and Accreditation Empowering Laboratory Personnel

Parametric Release Regulatory Requirements. Terry E. Munson Technical Vice President PAREXEL International, LLC

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

SAFETY DATA SHEET. Section 1: Identification of the substance/mixture and of the company/undertaking. Section 2: Hazards identification

FOR PLANT PROTECTION PRODUCTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS

Powerful Germ Kill, PURELL Peace of Mind. KILLS NOROVIRUS IN 30 SECONDS. NO RINSE REQUIRED. PURELL Foodservice Surface Sanitizer

Defoaming Surfactants

Industrial and Institutional Cleaning

Reducing the risk of allergen contamination in the factory

SCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).

Transcription:

Cleaning validation Presented by Marc Fini 21 May, 2013

What is cleaning validation? Cleaning validation is documented evidence that the cleaning process can effectively and reproducibility clean equipment to a predefined acceptable level. Slide 2 PharmOut 2013

What does CLEAN mean? Oxford Dictionary definition: To be free from dirt, marks, or unwanted matter Slide 3 PharmOut 2013

Types of cleaning Clean in Place (CIP) Skid WFI System Recirculation Clean out of place Equipment washer Loading patterns Manual Cleaning Brushes Procedural Operator Slide 4 PharmOut 2013

Cleaning agents Solvent: A substance, usually a liquid, capable of dissolving another substance Water (WFI, RO, Municipal Supply) Ethanol or other organic solvents Detergent solutions Acidic or Caustic Solutions Placebos Slide 5 PharmOut 2013

Cleaning agents Solute: A substance dissolved in another substance, usually the component of a solution present in the lesser amount. API Excipients Cleaning Agents Degradation Products Solvents Intermediates Slide 6 PharmOut 2013

Cleaning modes of action Physical High Pressure Spray High Velocity Flow Scrubbing Vacuuming Slide 7 PharmOut 2013

Cleaning modes of action Chemical Solubility Emulsification Wetting Chelation Dispersion Hydrolysis Oxidation Like dissolves Like Slide 8 PharmOut 2013

Examples of critical process parameters Temperature Pressure Flow Contact Time Cleaning Agent Concentration Dirty Hold Time Clean hold conditions Slide 9 PharmOut 2013

Examples of critical quality attributes Visual detection Cleaning Agent Residues Product Residues Microbiological residue limits Drainability/drying Conductivity/resistivity Slide 10 PharmOut 2013

Performing cleaning validation 1. 2. 3. 4. 5. 6. 7. Create a Cleaning Validation Team Write a Cleaning Validation Master Plan Collect Information Group products Set limits Group equipment Determine Sampling Sites Slide 11 PharmOut 2013

Performing cleaning validation 8. 9. 10. 11. 12. 13. Select Analytical Method Perform Recovery Studies Perform an Engineering Study Perform the Cleaning Validation Study Write a Validation Summary Report Implement Cleaning Procedures 14. Monitoring Slide 12 PharmOut 2013

Create a team Cross-functional/departmental team: Quality Assurance Operations/Manufacturing Engineering & Maintenance Validation Research and Development (R&D) Medical Affairs Regulatory Affairs Slide 13 PharmOut 2013

Cleaning validation master plan Documents the rationale and important aspects of the cleaning validation program: Purpose and Scope Responsibility Validation Approach Risk Assessment Acceptance Criteria Assessment for the Removal and Toxicity of Drug Product Formulation Excipients Slide 14 PharmOut 2013

Cleaning validation master plan Validation for the removal of Cleaning agents Defining Equipment Train for Cleaning Validation Equipment Train Surface Area Calculation Product Grouping Equipment Bracketing Selection of Sampling Sites Validation of 'Dirty' Holding Periods Validation of 'Clean' Holding Periods Single use Components Dedicated Equipment Slide 15 PharmOut 2013

Cleaning validation master plan Analytical Methodology Development of Analytical Methods Product Specific versus Product Non-Product Specific Analytical Methods Sensitivity Requirements for Cleaning Validation Samples Recovery Studies Sampling Methodology for Cleaning Verification and Cleaning Validation Monitoring Program Slide 16 PharmOut 2013

Cleaning validation master plan Data Collection Deviations & Deficiencies Handling Change Control Reporting Protocol Execution Validation Summary Reports (VSR) Routine Monitoring Slide 17 PharmOut 2013

Collect information about the products Dosage, toxicity, concentrations Excipients, degradants and impurities Material compatibility/interactions Solubility in water and in the cleaning agent Stability of product Difficulty of cleaning Slide 18 PharmOut 2013

Collect information about the equipment Define the equipment train and sequence in which equipment is used Materials of Construction Surface Finish Geometry (hard to reach areas) Surface Area Disassembly and Assembly Requirements Condition and suitability of equipment Slide 19 PharmOut 2013

Collect information about the process attributes Product list including media, buffers and non-routine cleaning agents Batch sizes Cleaning procedures Cleaning agents Cleaning temperature requirements clean and dirty holding times Slide 20 PharmOut 2013

Collect information This is the most difficult and time consuming part of any cleaning validation program, but if the information is complete and accurate it will prove to be highly beneficial at later stages of the validation process. Slide 21 PharmOut 2013

Group products If possible, group products and select a worst-case or representative product by considering: Solubility in water and proposed cleaning agent(s) Therapeutic dose Toxicity (e.g. LD50) Affinity to certain materials of construction Interaction with product which will follow on? Equipment train Product characteristics Class of drug Slide 22 PharmOut 2013

Group products Whilst this can significantly reduce the validation effort, ensure that each product selection is documented, scientifically justified and defendable in an audit situation. Slide 23 PharmOut 2013

Calculate limits Limits and acceptance criteria should be: Practical Verifiable Achievable Scientifically Sound Slide 24 PharmOut 2013

Calculate limits MAC =MDD x SF x MBS LDD MAC = Maximum Allowable Carryover MDD = the minimum daily dose of the active of cleaned product SF = Safety Factor, which is typically 0.001 or 1/1000 MBS = the Minimum Batch Size of the next product LDD = the largest daily dose of the next drug product to be manufactured in the same equipment Slide 25 PharmOut 2013

Calculate limits. Largest Daily Dose 2 units 10 µg 10 µg 1/1000 Safety Factor 10 mg Minimum Daily Dose Minimum Batch Size 50,000 units Slide 26 PharmOut 2013

Calculate limits Example: MDD (Product A) = 10 mg Safety Factor = 1/1000 or 0.001 MBS (Product B) = 50,000 units LDD (Product B) = 2 units Surface Area (Equipment Train) = 75,000 cm 2 MAC (µg/cm2 ) = 10 x 0.001 x 50,000 2 x 75,000 = 3.3 µg/cm 2 Slide 27 PharmOut 2013

Calculate limits Other methods to calculate limits: Using LD50 and modifying factor (determined by toxicologist) Default limits such as 10 ppm LD 50 = 50% lethal dose of the target residue in an animal, typically in mg/kg of body weight 10 ppm = 10 mg of residue per litre of next batch Slide 28 PharmOut 2013

Calculate Limits: Visually clean Visually clean acceptance criteria may be considered appropriate for dedicated equipment however possible degradants and bioburden need to be considered. Equipment should always be inspected when dry Minimum visual limit should be established in terms of amount Slide 29 PharmOut 2013

Group equipment Same design but differs only in size It may be acceptable to only validate the largest and smallest of each item (e.g. vessels?). Dedicated and shared equipment Same material of construction Slide 30 PharmOut 2013

Group equipment As with the product grouping, ensure that each equipment grouping is scientifically justified and defendable in an audit situation. Slide 31 PharmOut 2013

Determine sampling sites A Riboflavin or Fluoroscein study to determine hard to clean area Representative surface with respect to different materials of construction Role in process likely to lead to build-up or difficult to clean areas Hot spots i.e. locations that are considered hard to clean or have complex geometries Critical sites i.e. locations that may disproportionately contribute residue to the next process (e.g. filling needles ) Slide 32 PharmOut 2013

Select analytical method New analytical methods should typically occur concurrently with the development of new products. Methods should be product specific Non-specific methods may be used if it is not possible or practical to use a specific method Method must be sensitive enough Method must be appropriately validated particularly in the expected residue limit working range Slide 33 PharmOut 2013

Select analytical method Specific Non specific HPLC GC/MS Total Organic Carbon (TOC) Conductivity UV/Vis ph Slide 34 PharmOut 2013

Recovery Studies The recovery studies should ordinarily be performed in conjunction with the development of the analytical methods Recovery studies are performed to establish the effectiveness of the sampling technique Should be done for all product contact surfaces, e.g. stainless steel, plastics, glass, gaskets and hoses Usually carried out in the laboratory using coupons to simulate the product contact surface Slide 35 PharmOut 2013

Recovery method Swab Recovery Generally 70% recovery required Less than 50% recovery needs a justification Typically 15-30% RSD between samples acceptable Slide 36 PharmOut 2013

Recovery studies Rinse Recovery Should be treated the same as swabs. Used for sampling areas that can t be reached by swabs. For example, transfer lines. Innovative ways may be required when applying or collecting rinsate. Slide 37 PharmOut 2013

Perform an engineering study It is very important that the cleaning process capability is well understood before any validation takes place. Develop a cleaning validation protocol and report to document findings. Validation should not be a learning exercise but a verification of what is already known about your process. Slide 38 PharmOut 2013

Perform the cleaning validation study Once the cleaning validation plans and protocols have been prepared and approved, it is time to execute it. Ensure the protocol and procedures to be validated are being followed correctly. Preparation and pre-determined acceptance criteria are crucial in achieving a successful cleaning validation outcome. Ensure that any deviations or exceptions/ observations are captured via an exception reporting system. Slide 39 PharmOut 2013

Validation summary report At the conclusion of the validation exercise, a validation summary report will bring together all the aspects of the validation and allow conclusions to be drawn regarding the suitability of the cleaning programme and overall compliance with the validation plan. Slide 40 PharmOut 2013

Implement the cleaning method Once all the cleaning validation is complete and approved then its time to implement the cleaning system into the production process. It is not acceptable to use a cleaning process that has not been adequately validated. Ensure implemented method is consistent with validation and has not been changed in the process. Slide 41 PharmOut 2013

Monitoring Once the cleaning process is validated revalidation is generally not required providing the process is appropriately managed by a change control system Review of the cleaning methods can be done during annual product reviews Routine monitoring of equipment can be done on a rotating basis Slide 42 PharmOut 2013

Common deficiencies Unsuitable equipment (Surface finish or poorly maintained e.g. diaphragm valves and surface of tanks) Scientifically unsound justifications for product and equipment groupings Cleaning methods does not consider critical process parameters (temperature or contact time) Cleaning methods are not followed or reflect actual validation Control and lifespan of gaskets and silicone hosing Removal of cleaning agents unvalidated Incorrect limits set Slide 43 PharmOut 2013